Key result
Coinjection of EOMA cells with a neutralizing antibody to MCP-1 completely prevented the development of hemangioendothelioma tumors in mice (0% vs 100% tumor development).
Why the study?
Does a neutralizing antibody to MCP-1 prevent tumor development in a murine model of hemangioendothelioma?
Does a neutralizing antibody to MCP-1 prevent tumor development in a murine model of hemangioendothelioma?
Absolute Event Rate: 0% vs 100%
This study provides the first in vivo evidence that MCP-1 is required for hemangioendothelioma proliferation and that anti-MCP-1 therapy can completely prevent the growth of these vascular proliferative lesions.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open whether MCP-1 inhibition merits human trials in vascular tumors.
Gordillo et al. (2004) studied Hemangioendothelioma. Neutralizing antibody to MCP-1 vs. EOMA cells injected alone was evaluated on Tumor development. Coinjection of EOMA cells with a neutralizing antibody to MCP-1 completely prevented the development of hemangioendothelioma tumors in mice (0% vs 100% tumor development).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: